COVID-19 vaccine surveillance report–week42


Average: 1 (1 vote)

SummaryFour coronavirus (COVID-19) vaccines have now been approved for use in the UK. Rigorousclinical trials have been undertaken to understand the immune response, safety profile andefficacy of these vaccines as part of the regulatory process. Ongoing monitoring of the vaccinesas they are rolled out in the population is important to continually ensure that clinical and publichealth guidance on the vaccination programme is built uponthe best availableevidence.UK Health Security Agency, UKHSA, formerlyPublic Health England (PHE),works closely withthe Medicines and Healthcare Regulatory Agency (MHRA), NHS England, and othergovernment, devolved administration and academic partners to monitor the COVID-19vaccination programme. Details of the vaccine surveillance strategy are seton the pageCOVID-19: vaccine surveillance strategy(1). As with all vaccines, the safety of COVID-19vaccines is continuouslybeing monitored by theMHRA. They conclude that overall, the benefitsof COVID-19 vaccines outweigh anypotential risks (2)